ALB and head and neck squamous cell carcinoma: That same year, the results of a phase II clinical trial (ChiCTR2000033506) were reported for toripalimab combined with albumin-bound paclitaxel and cisplatin in the treatment of LA HNSCC patients, with an ORR of 92%, a median follow-up time of 17 months, a 1-year overall survival rate of 96.0%, and a 1-year DFS rate of 88% (15).